Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBIT (2022 - 2025)

Historic EBIT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' EBIT fell 14458.34% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 5004.46%. This contributed to the annual value of -$3.1 million for FY2024, which is 9543.39% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported EBIT of -$53.2 million as of Q3 2025, which was down 14458.34% from -$47.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year EBIT high stood at $47.2 million for Q4 2024, and its period low was -$53.2 million during Q3 2025.
  • Over the past 4 years, ARS Pharmaceuticals' median EBIT value was -$15.4 million (recorded in 2022), while the average stood at -$16.3 million.
  • Per our database at Business Quant, ARS Pharmaceuticals' EBIT plummeted by 22476.36% in 2023 and then soared by 56153.92% in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' EBIT stood at -$15.4 million in 2022, then soared by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then plummeted by 212.7% to -$53.2 million in 2025.
  • Its EBIT stands at -$53.2 million for Q3 2025, versus -$47.6 million for Q2 2025 and -$37.2 million for Q1 2025.